From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

Postexposure Vaccination Will Prevent Hepatitis A

For some exposed individuals, it works as well as immune globulin injections.

For years the CDC-recommended postexposure prophylaxis for hepatitis A was an injection of immune globulin (IG). Hepatitis A vaccination has recently become the preferred prophylaxis in some cases, partially because of the results of this large blinded study, which received some financial support from the vaccine manufacturer. The study was performed in Kazakhstan, where hepatitis A is considerably more common than in the U.S.

Household or day-care contacts, aged 2 to 40, were randomized to receive one dose of either immune globulin or vaccine within 14 days of exposure. A tiny minority of contacts in both groups (about 4% of vaccine recipients vs. about 3% of IG recipients) developed symptomatic hepatitis A, diagnosed by both serologic and clinical criteria. These results indicated that vaccine was noninferior to IG, which has an estimated prophylactic efficacy of 80% to 90%. Some variables suggested that IG patients had milder breakthrough disease than vaccine patients.

Comment: Shot for shot, the hepatitis A vaccine has many advantages over immune globulin, including better availability, easier administration, and longer duration of protection; both treatments are similar in cost. Whether vaccine is as effective as IG for infants younger than 12 months, adults older than 40, or those with chronic liver disease or immunocompromise (all of whom were excluded from this trial) awaits more data — for these individuals, the CDC continues to recommend IG as well as vaccination if indicated.

Abigail Zuger, MD

Published in Journal Watch General Medicine November 1, 2007

Citation(s):

Victor JC et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med 2007 Oct 25; 357:1685.

Baker CJ. Another success for hepatitis A vaccine. N Engl J Med 2007 Oct 25; 357:1757.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2007. Massachusetts Medical Society. All rights reserved.